Insulin Lispro
- Generic Name
- Insulin Lispro
- Brand Names
- Admelog, Humalog, Humalog Mix, Humalog kwikpen, Liprolog, Lyumjev, Insulin lispro Sanofi, Lyumjev (previously Liumjev)
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 133107-64-9
- Unique Ingredient Identifier
- GFX7QIS1II
- Background
Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is release...
- Indication
本品尤其适用于下列情况：
1.经常发生低血糖的1型糖尿病者，使用本品可减少低血糖的发生率；
2.生活不规律，外出活动较多的用胰岛素治疗的糖尿病患者，本品快速、短效的特点有助于及时调整胰岛素的用量。
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM)
- Associated Therapies
- -
A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients
- Conditions
- Interventions
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2011-05-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 374
- Registration Number
- NCT00666718
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Bromwich, West Midlands, United Kingdom
Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2008-02-05
- Last Posted Date
- 2010-08-31
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 289
- Registration Number
- NCT00607087
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide
- Conditions
- Interventions
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2011-01-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 339
- Registration Number
- NCT00560417
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yabucoa, Puerto Rico
A Study for Type 2 Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2007-10-24
- Last Posted Date
- 2010-09-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 426
- Registration Number
- NCT00548808
- Locations
- 🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)
- Conditions
- Interventions
- First Posted Date
- 2007-08-03
- Last Posted Date
- 2010-10-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 471
- Registration Number
- NCT00510952
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)
- Conditions
- Interventions
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2009-11-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 442
- Registration Number
- NCT00494013
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yung-Kang, Tainan, Taiwan
Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-06-18
- Last Posted Date
- 2010-11-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 387
- Registration Number
- NCT00487240
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation
Comparison of Insulins Aspart and Lispro in Insulin Pumps
- Conditions
- Interventions
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Tulane University Health Sciences Center
- Target Recruit Count
- 20
- Registration Number
- NCT00461331
- Locations
- 🇺🇸
Clinical Translational Unit - Tulane School of Medicine, New Orleans, Louisiana, United States
Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2010-03-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 191
- Registration Number
- NCT00348374
- Locations
- 🇵🇷
Pfizer Investigational Site, San Juan, Puerto Rico
Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-01-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1116
- Registration Number
- NCT00191282
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Liverpool, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.